Search results for "TREATMENT"

showing 10 items of 17623 documents

Identification of a Peptide Produced by Bifidobacterium longum CECT 7210 with Antirotaviral Activity

2016

Rotavirus is one of the main causes of acute diarrhea and enteritis in infants. Currently, studies are underway to assess the use of probiotics to improve rotavirus vaccine protection. A previous work demonstrated that the probiotic strain Bifidobacterium longum subsp. infantis CECT 7210 is able to hinder rotavirus replication both in vitro and in vivo. The present study takes a systematic approach in order to identify the molecule directly involved in rotavirus inhibition. Supernatant protease digestions revealed both the proteinaceous nature of the active substance and the fact that the molecule responsible for inhibiting rotavirus replication is released to the supernatant. Following pur…

0301 basic medicineMicrobiology (medical)RotavirusBifidobacterium longummedicine.medical_treatment030106 microbiologylcsh:QR1-502PeptideBiologymedicine.disease_causeMicrobiologylcsh:Microbiologylaw.inventionMicrobiology03 medical and health sciencesProbioticfluids and secretionslawRotavirusmedicineB. longum subsp. infantis CECT 7210Original Researchchemistry.chemical_classificationProteaseMolecular massProbiotics11-mer peptidebiology.organism_classificationRotavirus vaccineIn vitroProteaseBiochemistrychemistryFrontiers in Microbiology
researchProduct

'Secondary prevention' against female HPV infection: literature review of the role of carrageenan.

2020

Introduction: Human papillomaviruses (HPVs) are common sexually transmitted pathogens, causally associated with cervical cancer and other anogenital cancers, as well as approximately 20% of head and neck cancers. The HPV vaccine is an exceptional primary prevention tool, but the question of adequate secondary-prevention strategies remains open. The aim of this review is to better clarify the role of carrageenan in HPV prevention-strategies. Areas covered: A comprehensive literature search was performed (PubMed/MEDLINE, Embase, Google Scholar, Cochrane Databases) to identify articles on the use of carrageenan against HPV infection. The studies were identified using combinations of the search…

0301 basic medicineMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_treatment030106 microbiologyCarrageenan papillomavirus prevention HPV microbicideMEDLINEAlphapapillomavirusBioinformaticsCarrageenanMicrobiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemVirologyMicrobicidemedicineSecondary PreventionAnimalsHumans030212 general & internal medicinePapillomavirus VaccinesCervical cancerbusiness.industryMechanism (biology)Papillomavirus InfectionsHPV infectionmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaCarrageenanInfectious DiseaseschemistryFemalebusinessAdjuvantExpert review of anti-infective therapy
researchProduct

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

2017

International audience; Background: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis. Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile.Objectives: To compare the in vivo activity of levofloxacin and moxifloxacin against M. tuberculosis strains with various levels of fluoroquinolone resistance.Methods: BALB/c mice were intravenously infected with 106M. tuberculosis H37Rv and three isogenic mutants: GyrA A90V, GyrB E540A and GyrB A543V. Treatment with 50 or 100 mg/kg levofloxacin and 60 or 66 mg/kg moxifloxacin was given orally every 6 h, for 4 we…

0301 basic medicineMicrobiology (medical)Tuberculosis[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationmiceExtensively Drug-Resistant Tuberculosis030106 microbiologyMicrobial Sensitivity TestsMicrobiologyMycobacterium tuberculosis03 medical and health sciences0302 clinical medicine[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationLevofloxacinMoxifloxacinIn vivo[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineAnimalsPharmacology (medical)heterocyclic compounds030212 general & internal medicinePharmacologyMice Inbred BALB ClevofloxacinbiologyChemistry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationExtensively drug-resistant tuberculosisMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationbacterial infections and mycosesFluoroquinolone resistanceAnti-Bacterial Agents3. Good health[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesDisease Models AnimalSafety profileTreatment OutcomeInfectious Diseasestuberculosis[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesbacteriamoxifloxacinFluoroquinolonesmedicine.drug
researchProduct

Milk and blood biomarkers associated to the clinical efficacy of a probiotic for the treatment of infectious mastitis

2016

Previous studies have shown the efficacy of oral administration of selected lactobacilli strains to treat mastitis. The objective of this study was to find microbiological, biochemical and/or immunological biomarkers of the probiotic effect. Women with (n=23) and without (n=8) symptoms of mastitis received three daily doses (109 cfu) of Lactobacillus salivarius PS2 for 21 days. Samples of milk, blood and urine were collected before and after the probiotic intervention, and screened for a wide spectrum of microbiological, biochemical and immunological parameters. In the mastitis group, L. salivarius PS2 intake led to a reduction in milk bacterial counts, milk and blood leukocyte counts and i…

0301 basic medicineMicrobiology (medical)UrinalysisAdministration OralMastitisUrineUrinalysisMicrobiologylaw.invention03 medical and health sciencesProbioticOral administrationlawHumansMedicineMilk Humanbiologymedicine.diagnostic_testbusiness.industryProbioticsLactobacillus salivariusfood and beveragesInterleukinbiology.organism_classificationmedicine.diseaseLactobacillus salivariusMastitisTreatment OutcomeBloodMilk030104 developmental biologyImmunologyLigilactobacillus salivariusbiology.proteinFemaleAntibodybusinessBiomarkersBlood Chemical AnalysisBeneficial Microbes
researchProduct

Broad Prebiotic Potential of Non-starch Polysaccharides from Oats (Avena sativa L.): an in vitro Study

2018

Abstract Prebiotics inducing the growth or activity of beneficial intestinal bacteria – probiotics producing short-chain fatty acids (SCFA) have lately received wide recognition for their beneficial influence on host intestinal microbiota and metabolic health. Some non-starch polysaccharides (NSP) are defined as prebiotics and oats being one of richest sources of NSP in grains are considered as potentially having prebiotic effect. However, information on fermentation of specific NSP of oats is limited. Moreover, bacterial cross-feeding interactions in which fermentation of prebiotics is involved is poorly characterized. Here, we report the exploration of new candidates for the syntrophic ba…

0301 basic medicineMicrobiology (medical)food.ingredientlcsh:QH426-470medicine.medical_treatmentlcsh:QR1-502PolysaccharideApplied Microbiology and BiotechnologyMicrobiologylcsh:MicrobiologyB. licheniformis03 medical and health scienceschemistry.chemical_compoundfoodmedicineotorhinolaryngologic diseasesHemicelluloseFood scienceBacillus licheniformischemistry.chemical_classificationbiologyPrebioticfungifood and beveragesGeneral Medicinebiology.organism_classificationB. ovatuslcsh:Genetics030104 developmental biologyAvenaOat NSPchemistryC. butyricumComposition (visual arts)FermentationprebioticsBacteriaPolish Journal of Microbiology
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

2021

Introduction: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy. Methods: A multicohort Marko…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationTreatment duration030106 microbiologyPopulationTreatment duration03 medical and health sciences0302 clinical medicineHealth careTreatment duration.Medicine030212 general & internal medicineeducationOriginal ResearchHepatitis C viruseducation.field_of_studyGlecaprevir/pibrentasvirbusiness.industryGlecaprevirPibrentasvirInfectious DiseasesItalyEmergency medicineObservational studyGlecaprevir / pibrentasvirHepatitis C virubusinessInfectious Diseases and Therapy
researchProduct

An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy

2021

Background & aims: Hydroxychloroquine (HCQ) and chloroquine (CQ) are anti-malarial drugs frequently used in the rheumatologic field. They were recently identified as potential therapeutic options for Coronavirus Disease (COVID-19). The present study aims to map and grade the diverse health outcomes associated with HCQ/CQ using an umbrella review approach. Methods: Umbrella review of systematic reviews of observational and intervention studies. For observational studies, random-effects summary effect size, 95% confidence interval, and 95% prediction interval were estimated. We also assessed heterogeneity, evidence for small-study effect, and evidence for excess significance bias. The quality…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyhydroxychloroquine030106 microbiologyDiseaseReviewlcsh:Infectious and parasitic diseaseslaw.inventionchloroquine03 medical and health sciences0302 clinical medicinesystematic reviewRandomized controlled triallawChloroquineInternal medicineDiabetes mellitusChloroquine; COVID-19; Hydroxychloroquine; umbrella review; COVID-19; Chloroquine; Humans; Hydroxychloroquine; SARS-CoV-2medicineHumanslcsh:RC109-216030212 general & internal medicineumbrella reviewbusiness.industrySARS-CoV-2COVID-19HydroxychloroquineChloroquineGeneral Medicinemedicine.diseaseConfidence intervalCOVID-19 Drug TreatmentInfectious DiseasesSystematic reviewObservational studybusinessmedicine.drugHumanHydroxychloroquine
researchProduct

Fast-Growing Alveolar Echinococcosis Following Lung Transplantation

2020

International audience; Alveolar echinococcosis is a rare but life-threatening infection caused by the parasiteEchinococcus multilocularis. Its natural history is characterized by a slow parasitic growth over several years. Increased incidence and shorter development delay have been reported in immune-compromised patients. We report the reactivation of aborted lesions within 12 months of lung transplantation leading to a fast-growing aggressive hepatic lesion. Timely identification of alveolar echninococcosis allowed prompt albendazole treatment and radical surgery leading to a favorable outcome 42 months after transplantation. However, close clinical, serological and radiological monitorin…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.medical_treatment030231 tropical medicinelcsh:MedicineCase ReportEchinococcus multilocularisliverAlbendazole03 medical and health sciences0302 clinical medicinemedicinelung transplantationImmunology and AllergyLung transplantationRadical surgeryMolecular Biology<i>Echinococcus multilocularis</i>immunosuppressionGeneral Immunology and Microbiologybiologybusiness.industryIncidence (epidemiology)lcsh:RImmunosuppression030108 mycology & parasitologybiology.organism_classification3. Good healthSurgeryNatural historyTransplantationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyparasiteEchinococcus multilocularisbusinessmedicine.drug
researchProduct

An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019

2020

Abstract Increased production of inflammatory cytokines and myeloid-derived suppressor cells occurs in patients with coronavirus disease 2019. These inversely correlated with perforin-expressing natural killer (NK) and CD3+ T cells. We observed a lower number of perforin-expressing NK cells in intensive care unit (ICU) patients compared with non-ICU patients, suggesting an impairment of the immune cytotoxic arm as a pathogenic mechanism.

0301 basic medicineMicrobiology (medical)medicine.medical_treatmentMDSCInflammationchemical and pharmacologic phenomenaNK cellsProinflammatory cytokineNatural killer cell03 medical and health sciences0302 clinical medicineImmune systemmedicineCytotoxic T cellcytotoxic cellcytotoxic cellsbiologybusiness.industryCOVID-19COVID-19; cytotoxic cells; inflammation; MDSC; NK cells030104 developmental biologymedicine.anatomical_structureCytokineInfectious DiseasesPerforinSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAinflammation030220 oncology & carcinogenesisImmunologybiology.proteinMyeloid-derived Suppressor Cellmedicine.symptombusinessClinical Infectious Diseases
researchProduct